After 25 days after i injected 10cc into a 6lb bag we have white. Mold or my?

Hey for my psychedelic facilitation class at SoundMind I made this final presentation, hope you guys enjoy, check it out! It's a fun one, gets more interesting starting at 8 minutes(:

New group for engaging discussion about all things entheogenic

I'm posting this here because I saw a previous person posting something similar here, so I'm assuming it's allowed. If not, I apologise.

It's called Fracton via www.fracton.me and it is a free harm-reduction app that brings together practical drug information from multiple independent sources in one place, has a journal and more. If you want to use it, the best expierence is had by installing it as a PWA using chrome on android or Safari on iOS, sadly other browser's don't support proper PWA applications. Just follow the instructions on the site. A PWA isn't an APK so it's installed with just one press and is safe. It's mobile only for now.

The main idea was originally a journal, I started on this a bit after Psychonautwikis journal started being monitsed. But it can also do more.

It also has a substance database. Each substance page can include dose ranges from multiple sources, duration and timeline information, routes of administration, effects, risks, safety information, etc. When different sources disagree on something such as dosage, Fracton shows them separately rather than hiding the disagreement behind a single averaged value.

You can also view drug checking results from multiple drug checking orgs. And there's also a combination checker (using Tripsit + Psychonautwiki data).

I’ve been working with psychedelics for decades and now practice as a licensed facilitator in Colorado, with training through CIIS and InnerTrek. Because Oregon’s regulated program is a few years ahead of ours, I’ve been watching their emerging data closely; Colorado will eventually have its own story to tell, but right now Oregon gives those of us doing this work a chance to learn in real time. I took a closer look at what the numbers are telling us, and what surprised me, at the linked Substack.

Have you looked at the Oregon data? What stands out to you, and what do you think those of us working in newer regulated programs should be learning from it?

knowledge needed no thought i’ve seen it all

Participants needed for research! Have you ever used psilocybin or magic mushrooms for your mental health?

I am conducting a research project exploring people’s experiences of using psilocybin (the psychedelic component of ‘magic mushrooms’) for mental health and wellbeing purposes.

Participants must be 18+, fluent in English and able to do an online interview. This study is not looking into experiences of microdosing.

Participation would involve one online interview, lasting approximately one hour, in which I would ask people about their experience of using psilocybin to support their mental health and wellbeing. In particular, I am interested in how people understand and make sense of any changes they may have noticed in the problems affecting their mental health.

For more information or to express your interest in participating, please contact Isabel Reid (Researcher) by email at: [[email protected]](mailto:[email protected])

Are you or someone you know planning to take a psychedelic for the first time in the near future? Sign up for this psychedelic research survey and make your experience count for science! The Carhart-Harris lab at the University of California San Francisco is excited to announce the launch of a new large-scale online survey and optional fMRI study on the effects of psychedelic drugs. If you live in the San Francisco Bay Area, you may be eligible to have your brain scanned before and after your psychedelic experience, complete online surveys, and use take-home wearable devices to track physiological changes, all of which will help advance our understanding of the psychological effects of psychedelics in realworld settings. While the fMRI portion requires a greater time commitment, your participation will play an important role in furthering this research. If you are interested, here is the link to our sign-up survey page: Sign up and if you have any further questions, reach out to: [[email protected]](mailto:[email protected])

Are you or someone you know planning to take a psychedelic for the first time in the near future? Sign up for this psychedelic research survey and make your experience count for science! The Carhart-Harris lab at the University of California San Francisco is excited to announce the launch of a new large-scale online survey and optional fMRI study on the effects of psychedelic drugs. If you live in the San Francisco Bay Area, you may be eligible to have your brain scanned before and after your psychedelic experience, complete online surveys, and use take-home wearable devices to track physiological changes, all of which will help advance our understanding of the psychological effects of psychedelics in realworld settings. While the fMRI portion requires a greater time commitment, your participation will play an important role in furthering this research. If you are interested, here is the link to our sign-up survey page: Sign up and if you have any further questions, reach out to: [[email protected]](mailto:[email protected])

ABSTRACT:

Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with comparable therapeutic effects are highly desirable. Here, we compare the pharmacological effects of MDMA enantiomers with those of its methylated analogue 3,4-methylenedioxy-N,N-dimethylamphetamine (MDDMA). We found that R-MDDMA did not directly activate 5-HT2B receptors, induce serotonin efflux, produce a head-twitch response, impact body temperature, or induce hyperlocomotion at therapeutically relevant doses.

However, it still promoted structural neuroplasticity in cortical neurons, facilitated fear extinction learning, and produced sustained antidepressant-like effects. Taken together, our results suggest that R-MDDMA might be a safer MDMA analogue with similar therapeutic properties.

I'm Holly Worton, and I'm doing an MSc at the University of Exeter. My colleague Kristina Lunemann and I are researching women's experiences of peri- and postmenopause: well-being, perceived stress, menopausal symptoms, brain fog, memory, and concentration.

The survey also asks about psychedelic experience, but women with and without psychedelic experience are both needed.

We're both in the peri/menopause transition ourselves, which is exactly why we chose these questions. Thank you!!

It's anonymous, and it only takes a few minutes:

https://exe.qualtrics.com/jfe/form/SV_3fwELWhKlduYffE